Germline genetic editing allows for disease prevention
Tetsuyaishii Ishii, 01-xx-2017,Tetsuya Ishii, Professor, Hokkaido University
Tetsuya Ishii, PhD, professor of Office of Health and Safety, Hokkaido University. In 2002, he joined Japan Science and Technology Agency (JST) and worked as a program officer. In 2005, he completed the international program officer training program in U.S. NIH. "Reproductive medicine involving genome editing: clinical uncertainties and embryological needs," No Publication,
Assisted reproductive techniques are practised with prior consent by parents. However, widely accepted assisted reproductive techniques such as IVF involve no intentional genetic intervention. Therefore, under what conditions does parental consent justify the germline genetic intervention from the viewpoint of a child's welfare? Consider the UK regulatory framework on mitochondrial transfer (). Such intervention is deemed legal provided the germline modification focuses mtDNA (not nuclear DNA) and intends to prevent the maternal transmission of ‘serious’ mitochondrial disease to offspring. This is employed when a mother carries the risk of transmitting the disease to the child. Its practice is limited to serious conditions among various forms of mitochondrial disease. Similarly, disease prevention via germline genome editing might be accepted in some countries. Notably, in the International Summit on Human Gene Editing, mitochondrial disease was addressed as a candidate for germline genome editing (). Interestingly, the elimination of pathogenic mtDNA using mito TALEN (mitochondria-targeted nucleases to selectively reduce mtDNA haplotypes) requires no oocyte donation, which is indispensable for mitochondrial donation in the UK (). Aside from cases of serious mitochondrial disease, the use of germline genome editing seems compelling in cases of definite inheritance of a serious or life-threating autosomal genetic disorder where preimplantation genetic diagnosis (PGD) is inapplicable, such as autosomal dominant diseases in which one or both parents is homozygous (e.g. Huntington disease) or autosomal recessive diseases where both parents are homozygous (e.g. cystic fibrosis) (). At least four reports have demonstrated that genome editing-mediated gene correction and the recovery of phenotypes are feasible in mouse and rat experiments (). In such rare cases, the benefits of genome editing for a prospective child is likely to exceed the risks, such as the failure of disease prevention and off-target mutations (, ). Therefore, parental consent for germline genome editing might be justifiable.